2020, the year HLB's grand goal began.
Chairman Yang-Gon Jin of HLB announced
HLB's strategy to become a global pharma.
Chairman Jin gave details of
HLB's preparations this morning for four items for global new drug development
(strong new drugs, development ability, capital, and speed) during the company
presentation of the 'Bio Korea 2020 Invest Fair', which was conducted online.
He said "Rivoceranib,
which has been marketed as a gastric cancer treatment for 5 years in China, is
a proven new drug that has obtained excellent efficacy data for numerous
indications with a total of 481 research papers published”, and added “with the
acquisition, Rivoceranib's royalty income from Hengrui Medicine will begin
coming in in the fourth quarter of this year, and global sales will begin next
year. "
"Reflecting on the past
12 years in the name of 'HLB', we actively engaged in M&A in order not to
lose in the speed battle with global pharmaceutical companies." chairman
also said, "with Apealea coming into the ovarian cancer treatment market,
starting from Germany, it will expand sales to other European countries and the
United States. ” He also expressed expectations about the COVID-19 vaccine
being developed by Immunomic Therapeutics, saying "the performance of the
COVID-19 vaccine will continue in the second half of next year."
"HLB is collaborating
with bio companies developing new drugs in various fields such as targeted
anti-cancer drugs, immuno-cancer drugs, cell therapies, sepsis, vaccines, and
brain tumor drugs through subsidiaries and affiliates," said Chairman Jin.
He did not forget to emphasize that “Through
the HLB Bio eco-System (HBS), which integrates the core competencies of R&D,
production, regulation, licensing, marketing, and related companies in the name
of HLB, it will minimize the trial and error that can occur during the
development of new drugs."
Bio Korea 2020, which is on
the 15th occasion, is the largest bio event in Korea designed to
inform the world of the capabilities of Korea's pharmaceutical and bio
industries. Numerous bio companies such as Celltrion, GC Cell, and ABL Bio
participated and are proceeding online in the aftermath of COVID-19 with
virtual exhibition halls.